Document Classification

Section Type: METHODS

Text: Patients received neoadjuvant epirubicin 90 mg/m (2) plus cyclophosphamide 600 mg/m (2) followed by paclitaxel 175 mg/m (2) (ECT), each 3-weekly for four cycles (n = 370), or epirubicin 150 mg/m (2) followed by paclitaxel 225 mg/m (2) with pegfilgrastim followed by CMF (cyclophosphamide 500 mg/m (2), methotrexate 40 mg/m (2), fluorouracil 600 mg/m (2)) on days 1 and 8 (E (dd) T (dd) CMF), each 2-weekly and for three cycles (n = 363).